The Role of CD133 in Normal Human Prostate Stem Cells and Malignant Cancer-Initiating CellsDonald J. Vander Griend, John T. Isaacs|Cancer Research|2008Cited by 233
Is the Achilles’ Heel for Prostate Cancer Therapy a Gain of Function in Androgen Receptor Signaling?Ivan V. Litvinov, John T. Isaacs|The Journal of Clinical Endocrinology & Metabolism|2003Cited by 211
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.Bruce Ruggeri, Craig A. Dionne, Diane E. Gingrich et al.|PubMed|2003Cited by 124
Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer MicroenvironmentJohn T. Isaacs, Tomas Leanderson, Lizamma Antony et al.|Cancer Research|2012Cited by 113
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumorsAnders Olsson, Tomas Leanderson, Anders Björk et al.|Molecular Cancer|2010Cited by 90